TrialAdvances in therapy2021

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.

Doreen Barrett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.